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Abstract
Background: In February 2005, the US Advisory Committee on Immunization Practices recommended the new
meningococcal conjugate vaccine (MCV4) for routine use among 11- to 12-year-olds (at the preadolescent health-
care visit), 14- to 15-year-olds (before high-school entry), and groups at increased risk. Vaccine distribution
started in March; however, in July, the manufacturer reported inability to meet demand and widespread MCV4
shortages were reported. Our objectives were to determine early uptake patterns among target (11-12 and 14-
15 year olds) and non-target (13- plus 16-year-olds) age groups. A post hoc analysis was conducted to compare
seasonal uptake patterns of MCV4 with polysaccharide meningococcal (MPSV4) and tetanus diphtheria (Td)
vaccines.
Methods: We analyzed data for adolescents 11-16 years from five managed care organizations participating in
the Vaccine Safety Datalink (VSD). For MCV4, we estimated monthly and cumulative coverage during 2005 and
calculated risk ratios. For MPSV4 and Td, we combined 2003 and 2004 data and compared their seasonal uptake
patterns with MCV4.
Results: Coverage for MCV4 during 2005 among the 623,889 11-16 years olds was 10%. Coverage for 11-12 and
14-15 year olds was 12% and 11%, respectively, compared with 8% for 13- plus 16-year-olds (p < 0.001). Of the
64,272 MCV4 doses administered from March-December 2005, 73% were administered June-August. Fifty-nine
percent of all MPSV4 doses and 38% of all Td doses were administered during June-August.
Conclusion: A surge in vaccine uptake between June and August was observed among adolescents for MCV4,
MPSV4 and Td vaccines. The increase in summer-time vaccinations and vaccination of non-targeted adolescents
coupled with supply limitations likely contributed to the reported shortages of MCV4 in 2005.
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Background
Menactra®, a quadrivalent meningococcal conjugate vac-
cine (MCV4) designed to prevent invasive disease due to
Neisseria meningitidis was licensed in the United States in
January 2005[1]. After consideration of disease epidemi-
ology, anticipated supply and estimated demand, in Feb-
ruary 2005, the Advisory Committee on Immunization
Practices (ACIP) recommended MCV4 for adolescents
ages 11 and 12 (at the preadolescent health-care visit)
and, for those not previously vaccinated, before high-
school entry (15 years old), and to persons at increased
risk of invasive disease, including college freshmen living
in dormitories[2]. This was the first N. meningitidis vaccine
recommended for routine vaccination of adolescents in
specific age groups. The recommendations also stated that
other adolescents, college students, and persons infected
with human immunodeficiency virus may elect to receive
the vaccine. Previously, the ACIP had recommended that
health care providers who care for college students (espe-
cially those living in dormitories) inform the students and
their parents about meningococcal disease and the
polysaccharide vaccine, Memomune® (MPSV4)[3]. Addi-
tionally, ACIP had recommended that colleges inform
students about the disease and the availability of MPSV4.
Distribution of MCV4 started in March, and ACIP recom-
mendations became official on May 30, 2005 (upon pub-
lication in the Morbidity and Mortality Weekly
Reports)[1]. Two months later, in July, the manufacturer
reported inability to meet demand and placed limits on
vaccine orders[4]. Additionally, on September 30, 2005,
Centers for Disease Control and Prevention (CDC) and
the Food and Drug Administration announced an investi-
gation of a possible association between MCV4 and Guil-
lain-Barré Syndrome (GBS)[5]. We analyzed data from 5
managed care organizations to study uptake patterns of
MCV4 among adolescents during 2005 in relation to ACIP
recommendations, and the timing of licensure through
the GBS investigation[6]. Additionally, because we
observed seasonal trends in MCV4 uptake, we sought to
determine whether the trend was typical of meningococ-
cal vaccines or other vaccines administered to adolescents.
Therefore, we conducted a post hoc analysis of 2003-2004
VSD data to examine seasonal uptake of MPSV4 and teta-
nus diphtheria (Td) among adolescents. A booster dose of
Td vaccine was recommended for adolescents at 11-12 or
14-16 years and every 10 years thereafter[7].
Methods
Vaccine Safety Datalink
The VSD is a collaborative project between CDC and eight
US managed care organizations (MCOs) who have
approximately six million members (2% of the US popu-
lation)[6]. MCOs participating in VSD use an automated
tracking system which records each vaccination adminis-
tered to its members in addition to gathering data on
member demographics and medical care utilization. The
VSD's main purpose is to help detect possible vaccine
related adverse events; however, VSD has also been uti-
lized to study uptake of various vaccines [8-11].
MCV4 Coverage
To examine MCV4 uptake during March-December 2005,
we used 2005 vaccination data for adolescents 11-16 years
of age from five of the eight MCOs (defined here as MCO
A-E) who participated in ongoing data analyses for vac-
cine adverse events [10,12]. The institutional review
board at each VSD site approved this study and agreed
that informed consent from individuals was not required
(Protocol #5126). We did not analyze data for 17 and 18
years olds because we could not determine which of the
17 and 18 year olds were college freshmen living in dor-
mitories and therefore, recommended to receive MCV4.
Additionally, in 2005, not all MCOs collected data for 18
year-olds.
Based on ACIP's recommendations for MCV4, adolescents
11-12 and 14-15 years of age were defined as "target" age
groups. Although the ACIP recommendations specified
15 years of age to approximate high school entry, we com-
bined 14 and 15 year olds to represent high school entry
because census data estimate that 64% and 22% of 9th
graders are 14 and 15 years of age, respectively [1,13].
Adolescents aged 13 or 16 years were combined into the
"13- plus 16-year-olds" year age group to represent the
comparison or "non-target" age group.
We calculated the number of MCV4 doses administered
by month and age group. To calculate MCV4 coverage, the
number of vaccinated adolescents was divided by the total
number of adolescents enrolled in the age group per
month. The monthly enrollment for each MCO was based
on 2005 data for all except MCO E; we used 2004 data for
MCO E because 2005 data were not available at the time
of this analysis. The yearly enrollment by age for each
MCO was estimated by averaging the 12 monthly totals.
We used SAS 9.1 to calculate chi-square p-values, risk
ratios and 95% confidence intervals for 11-12 year olds
and 14-15 year olds to receive MCV4 compared to 13-
plus 16-year-olds.
Additionally, in February 2006, we queried each of the
five MCO principal investigators about whether or not: 1)
the MCO experienced a "vaccine shortage" during 2005
and 2) if they were aware of any local or state legislation
that could have impacted MCV4 during 2005.
Td and MPSV4 Uptake
We focused on the Td vaccine because it was the only vac-
cine recommended for adolescents during 2003-2004;
unlike hepatitis B, measles mumps and rubella, and vari-
cella vaccines, it is not recommended until age 11-12 andBMC Infectious Diseases 2009, 9:175 http://www.biomedcentral.com/1471-2334/9/175
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is not given in young children. For Td uptake, we com-
bined preservative-free and non-preservative free tetanus
and diphtheria toxoids, adsorbed, for adult use. To esti-
mate MPSV4 and Td uptake, we combined 2003 and 2004
VSD data for adolescents 11-16 years of age from the same
five MCOs (i.e A-E) used for examining MCV4 uptake.
Two years of data were combined to maximize sample size
and allow us to examine vaccination trends before MCV4
was licensed. Coverage for MPSV4 was not calculated
since this vaccine was not routinely recommended for all
11-16 year old adolescents and eligibility (i.e. denomina-
tor) could not be accurately ascertained in this study. Sim-
ilarly, Td coverage was not estimated because the
indications for Td use (e.g. for use after tetanus-prone
injury) were not known. 2005 data were not analyzed
since the introduction of MCV4 likely affected the uptake
patterns of MPSV4 (i.e. MCV4 substituted for MPSV4) and
Td (e.g. uptake increased perhaps due to more immuniza-
tion visits related to introduction of MCV4).
Therefore, for both MPSV4 and Td, we calculated the
number of doses administered by month. MPSV4 uptake
is presented for all adolescents 11-16 years combined
because of low overall uptake. Td uptake is presented by
single year of age from 11-16 years because 1) grouping
distorted the patterns observed for single year of age and
2) Td recommendations did not parallel those of MCV4.
Results
MCV4 Uptake
The number of adolescents 11-16 years of age in the five
MCOs totaled 623,889 (Table 1). Enrollment in the five
MCOs ranged from about 13,000 to 298,000 and the two
largest MCOs made up 90% of the study population. At
the end of 2005, 64,272 vaccinations were administered
and the overall coverage was 10% among adolescents 11-
16 years of age (Table 1). Coverage was highest among 11-
12 year olds (12.3%), followed by 14-15 year olds
(10.5%), and lowest among the non-target, 13+16 year
group (8.2%). The risk ratios for receiving MCV4 for ages
11-12 and 14-15 years compared to 13- plus 16-year-olds
were 1.51 (95% Confidence Interval (CI): 1.48-1.54) and
1.29 (95% CI: 1.26-1.31), respectively. Of the 64,272 vac-
cinations, 38%, 35% and 27% were administered to 11-
12, 14-15 and 13+16 year olds, respectively.
The coverage by MCO for all adolescents combined
ranged from 7% to 30%; the lowest coverage was in the
two largest MCOs (D and E). Coverage for the 11-12 and
14-15 year groups ranged from 6% to 34% and 8% to
32%, respectively (Table 1). At each MCO, these two tar-
get age groups were more likely to be vaccinated than the
non-target group (p < 0.001) with the exception of age
group 14-15 at MCO C and 11-12 at MCO D. MCO C, D
and E reported having some vaccine shortages. Of these
three, MCO D recommended that given the shortage, pro-
viders selectively offer MCV4 only to patients at increased
risk for meningococcal disease including college freshmen
living in dormitories; adolescents 11-12 years and those
starting high school were to be deferred to avoid exhaust-
ing MCV4 supplies.
Figure 1 shows the percent of adolescents vaccinated by
month and age group during 2005 for all 5 MCOs com-
bined. Vaccine uptake began in March and started to
increase in May, peaked in July, and declined until Octo-
ber, 2005, remaining level thereafter. Of the 64,272 total
MCV4 vaccinations administered, 73% were administered
during June, July and August (21%, 26% and 26%, respec-
tively).
MPSV4 Uptake
During 2003-2004, a total of 1,837 MPSV4 vaccinations
were administered to adolescents 11-16 years of age.
Table 1: MCV4 uptake during 2005 among 11-16 year old adolescents by MCO and age group
MCO Local or state 
MCV4 
Legislation§
MCV4 
shortage 
during 2005§
Study
Population
All adolescents Number (%) 
Vaccinated
Percent Vaccinated by Age Group
11-12 14-15 13+16
(Ref)
A Yes† No 19724 3680 (18.7) 33.7* 13.8* 9.6
B No No 31404 9518 (30.3) 31.9* 32.0* 27.0
C No Yes 13456 1832 (13.6) 15.2* 13.4 12.3
D Unknown‡ Yes 261544 17934 (6.9) 6.4 7.7* 6.4
E Unknown‡ Yes 297761 31308 (10.5) 13.9* 10.3* 7.5
All MCOs -- -- 623889 64272 (10.3) 12.3* 10.5* 8.2
MCV4 - Meningococcal conjugate vaccine
MCO - Managed care organization
§Based on self-report by principal investigator at each MCO
†MCO is located in a state with legislation requiring meningococcal vaccination for adolescents in residential schools and postsecondary institutions 
that provide housing for students.
‡MCO did not provide a response; however, the state(s) these MCOs are located in did(do) not have any meningococcal vaccination legislation[24].
*p < 0.001 when compared to 13+16 year groupBMC Infectious Diseases 2009, 9:175 http://www.biomedcentral.com/1471-2334/9/175
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Uptake for 11-16 year olds started to increase in May and
peaked in June (Figure 2). Of the total doses, 45% were
administered during June, July and August (21%, 14%
and 10%, respectively).
Td Uptake
During 2003-2004, a total 240,480 Td vaccinations were
administered to adolescents 11-16 years of age. The
number of vaccinations administered decreased with age,
ranging from 29% among 11 year olds to 5% in the 16
year olds (data not shown). Overall, adolescents 11 and
12, 13 and 14, and 15 and 16 years of age appear to have
similar seasonal patterns with the number of vaccinations
rising substantially from May to June and peaking in
August (Figure 3). Additionally, 11-13 year olds also had
a smaller increase in uptake starting in March. Of the total
number of vaccinations, 10%, 12%, 15% were adminis-
tered during June, July and August, respectively.
Percent of 11-16 year-olds vaccinated with MCV4, for all 5 MCOs combined, 2005 Figure 1
Percent of 11-16 year-olds vaccinated with MCV4, for all 5 MCOs combined, 2005. MCV4 - Meningococcal conju-
gate vaccine; MCO - Managed care organization. i - Jan 14, 2005 - Food and Drug Administration (FDA) licenses MCV4. ii - Feb 
10, 2005 - Advisory Committee on Immunization Practices (ACIP) recommends MCV4. iii - May 30, 2005 - ACIP recommen-
dations published (become official). iv - July 19, 2005 - MCV4 manufacturer announces limits on MCV4 orders. v - Sep 30, 2005 
- FDA and Centers for Disease Control and Prevention announce an investigation of a potential link between MCV4 and Guil-
lain-Barré Syndrome.
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Number of 11-16 year-olds vaccinated with MPSV4, for all 5 MCOs combined, 2003-2004 Figure 2
Number of 11-16 year-olds vaccinated with MPSV4, for all 5 MCOs combined, 2003-2004. MPSV4 - Meningococcal 
polysaccharide vaccine; MCO - Managed care organization.
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Discussion
MCV4 coverage during the first ten months after its licen-
sure (March-December 2005) was about 11% among tar-
geted adolescents. Non-targeted adolescents (13 and 16
year olds) received a sizeable portion (27%) of the total
administered doses. Of the five MCOs, the two largest
reported vaccine shortages and had the lowest coverage.
The surge in MCV4 uptake during the summer months
coupled with the uptake among non-targeted adolescents
likely contributed to the vaccine ordering limits and
reported shortages. Seasonal uptake patterns of MPSV4
and Td (prior to MCV4 availability) show a similar
increase in uptake during the summer, though the month
of the peak uptake varied.
Prior to the availability of national coverage data,[14]
most vaccination coverage information for adolescents
came from cross-sectional or before-and-after studies
designed to evaluate the impact of immunization require-
ments, voluntary school-based programs, and interven-
tion designed to increase the delivery of clinical
preventive services [15-20]. In general, these studies have
revealed only limited uptake of newly recommended vac-
cines for adolescents before the implementation of inter-
ventions that were being studied. Other studies of vaccine
uptake in adolescents have shown similarly modest
uptake[8,21,22]. The first nationally representative physi-
cian-validated adolescent immunization survey (National
Immunization Survey-Teen) found that MCV4 coverage
among US adolescents 13-17 years was 12% during
2006[14]. Our results demonstrate that the VSD can be an
important data source for timely evaluation of new or
expanded vaccine recommendations given their use of a
real-time surveillance system[12].
Vaccine uptake among adolescents appears to have a sea-
sonal pattern. MCV4 uptake started increasing in May and
peaked in July. Examination of MPSV4 and Td also shows
increases in uptake during summer months. The earlier
peak for MPSV4 suggests that different factors may play a
role; however, given the small number of MPSV4 vaccina-
tions (compared to Td and MCV4), it is difficult to
hypothesize possible reasons. It is possible that MCV4
would have peaked in August (before the start of school),
like Td, if not for the vaccine limits placed by the manu-
facturer (in July). Michigan's vaccine registry data showed
a similar surge in MCV4 uptake during summer months
suggesting that this seasonal increase is not limited to
adolescents enrolled in managed care [21]. The GBS inves-
tigation was announced on September 30, 2005, and by
then vaccine uptake had declined substantially. Although
we cannot ascertain whether the decline between Septem-
ber and October was related to the GBS investigation, the
impact of the investigation, if any, was likely minimal in
this study population given the similar trend observed for
Td.
Coverage was lower in the three MCOs reporting short-
ages (MCO C, D, and E) than in the other two. This
included the two largest MCOs where implementation of
a new vaccine recommendation is likely more challenging
compared to smaller MCOs. Coverage differences within
and between MCOs could have been affected by the
nature of the shortage and/or the implementation plan at
the MCO; we were unable to gather detailed information
from all MCOs. The low coverage among the targeted ado-
lescents in MCO D was likely related to their change in
policy due to the shortage which instructed providers to
defer vaccinating 11-12 and 14-5 year olds and preferen-
Number of Td vaccinations administered to 11-16 year-olds, for all 5 MCOs combined, 2003-2004 Figure 3
Number of Td vaccinations administered to 11-16 year-olds, for all 5 MCOs combined, 2003-2004. Td - Tetanus 
diphtheria vaccine; MCO - Managed care organization.
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tially vaccinate college freshman. School immunization
laws have had a marked impact on both the incidence of
vaccine preventable disease and immunization coverage
in the United States. A limited number of studies suggest
that much of the success of adolescent immunization pro-
grams in the United States is a direct result of these
requirements[16,23]. During our study period, none of
the MCOs were affected by statewide MCV4 legislation
(Table 1)[24].
In February 2005, the ACIP carefully considered supply,
anticipated demand and disease epidemiology when rec-
ommending routine use of MCV4 for adolescents 11-12
and 14-15 years of age[25]. At the same meeting, the man-
ufacturer projected producing about 5 million doses in
2005[26] and the 2005 CDC Annual Biosurveillance data
(CDC unpublished data) show that the manufacturer
reported distributing about 3.1 million doses in 2005.
The 2005 MCV4 mismatch between supply and demand
and the reported shortages likely resulted from a combi-
nation of factors, including the increase in uptake over the
summer, vaccination of non-targeted groups, and a sup-
ply shortfall possibly related to manufacturing capacity.
Additionally, analysis of insurance claims data (presented
by the MCV4 manufacturer at the June 2006 ACIP meet-
ing) showed that from March-August 20, 2005, among
adolescents, Menactra was administered more commonly
to 18 year olds than other age groups [27]. This also likely
contributed to the reported shortages. Uptake among 18
year olds could not be assessed in this study because not
all MCOs collected data for this group. Based partly on
our findings, a supply-demand imbalance was anticipated
the following summer (2006) leading ACIP to recom-
mend in May 2006 that MCV4 administration to 11-12
year olds be deferred; that supply limitation was resolved
in November 2006[28,29]. In August 2007, ACIP changed
their MCV4 recommendation to include routine vaccina-
tion of all adolescents 11-18 years partly to simplify pro-
vider decisions to vaccinate[30].
This study has some limitations. First, these results based
on the VSD data may not be generalizable to uninsured
adolescents and coverage during 2005 was likely lower in
the overall US adolescent population; however, with
standardized protocols, VSD data can be used to obtain
timely vaccination coverage of recently and newly recom-
mended vaccination. Second, we could not account for
vaccinations that might have been administered outside
the VSD MCO; however, considering the high price of
MCV4 (list price in 2005 was $82), it is unlikely that many
adolescents received this vaccine outside the plan. Third,
this study is unable to account for the effect of any local
events on seasonality of vaccination trends such as a case
of meningococcal disease. Finally, we could have underes-
timated coverage among the target groups due to misclas-
sification; some adolescents included in the 13+16 year-
old, "non-target" age group, may in fact have been vacci-
nated according to recommendations if they were starting
high school at those ages. However, the impact on our
estimates is likely negligible given US school enrollment
estimates.
Conclusion
These data from the VSD confirm the anecdotal reports of
providers that vaccinations increase during summer
months. This seasonal trend is likely related to vaccina-
tion requirements for summer recreational activities,
upcoming school requirements and convenience for par-
ents. Parents need to recognize that regular preventive vis-
its provide an opportunity for obtaining timely
vaccinations. In addition, the comparatively high propor-
tion of vaccine doses administered to adolescents outside
of the target groups illustrates the challenges associated
with implementing complex vaccination recommenda-
tions. These factors combined with the limitations in vac-
cine supply resulted in a failure to meet MCV4 demand
during the summer of 2005, and should be considered in
the future as new vaccines are recommended to avoid
potentially preventable shortages. Avoiding supply dis-
ruptions is essential to a key aspect of increasing vaccina-
tion in adolescents: reduction of missed opportunities for
vaccinations during all healthcare visits.
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